Clinton Foundation
At a press conference in New York on May 8 President Clinton announced significant price reductions for second-line HIV/AIDS treatment.
New agreements have been made with the generic drug manufacturers Cipla and Matrix that lower the prices for 16 ARV formulations.
These formulations will be available to 66 developing countries in Africa, Asia, Latin America and the Caribbean through the Clinton Foundation’s Procurement Consortium. The new prices will generate an average savings of 25 % in low-income countries and 50 % in middle-income countries.
These price reductions have been made possible by UNITAID, the international drug purchase facility established in 2006 by France, Brazil, Chile, Norway and the UK. UNITAID will provide the Clinton Foundation HIV/AIDS Initiative (CHAI) with more than $100 million to buy second-line medicines for 27 countries through 2008.
Read the entire press release here /arrow_news.gif)
|
Second-line treatment is required for patients who develop resistance to first-line treatment and currently costs 10 times the price of first-line therapy. Nearly a half million patients will require these drugs by 2010.
|
Go to News archive /arrow_news.gif)
|
